

Conatus Pharmaceuticals Investor Relations Department 16745 W. Bernardo Drive Ste 200 San Diego, CA 92127 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: CNAT Last Trade: 6.14 Trade Time: 11:03 AM ET Jul 25, 2017 Change: -0.05 ♣ (-0.808%) Day Range 6.12 - 6.23 52-Week Range 1.45 - 9.40 Volume 77,043

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Stock Performance



Press Releases [View all]

Jul 6, 2017

Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of \$7 Million Payment

Jun 26, 2017

FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC

Jun 16, 2017

<u>Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference</u>

May 16, 2017

Conatus Announces Completion of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

May 11, 2017

Conatus Announces Pricing of Public Offering of Common Stock

Financials [View all]

First Quarter Financial Results

Mar 16, 2017

Annual Report (10-K)

Apr 28, 2017

Proxy Statement (DEF 14A)

May 5, 2017

Quarterly Report (10-Q)

Nov 8, 2016

Quarterly Report (10-Q)

Aug 5, 2016

Quarterly Report (10-Q)